


We claim:

1. A compound selected from the group consisting of the formula:



where R_1 is an aromatic structure, an alicyclic structure, a branched aliphatic

- 5 structure or a linear aliphatic group having 5 to 15 carbons; and

R_2 is an aliphatic chain having 10 to 18 carbons;


R_3 is a tertiary amine; and

R_4 is a group that is selectively hydrolyzed in a target cell.

- 10 2. The compound of Claim 1 wherein R_3 is pyrrolidino.

3. The compound of Claim 1 wherein R_4 is selected from the group

consisting of an acetyl, $-\text{CO}(\text{CH}_2)_n\text{CH}_3$ wherein n is at least 1 and
 wherein R_5 is an alkyl group.



15

4. The compound of Claim 1 wherein R_1 is 4-hydroxyphenyl.

5. The compound of Claim 1 wherein R_1 is 3,4-ethylenedioxy.

- 20 6. A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.

7. A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.

5

8. A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.

10

9. A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.

15


10. A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.

20


11. A vaccination method comprising the steps of:

- a). removing cancer cells sensitive to the compounds below from a patient;
- b). treating the cancer cells *in vitro* with an effective amount of a composition comprising the compound of Claim 1 and pharmaceutically acceptable salts thereof.


20040309 031002

[illegible][illegible][illegible]

	(1)	(2)	(3)	(4)	(5)	(6)	(7)	(8)	(9)	(10)	(11)	(12)	(13)	(14)	(15)	(16)	(17)	(18)	(19)	(20)	(21)	(22)	(23)	(24)	(25)	(26)	(27)	(28)	(29)	(30)	(31)	(32)	(33)	(34)	(35)	(36)	(37)	(38)	(39)	(40)	(41)	(42)	(43)	(44)	(45)	(46)	(47)	(48)	(49)	(50)	(51)	(52)	(53)	(54)	(55)	(56)	(57)	(58)	(59)	(60)	(61)	(62)	(63)	(64)	(65)	(66)	(67)	(68)	(69)	(70)	(71)	(72)	(73)	(74)	(75)	(76)	(77)	(78)	(79)	(80)	(81)	(82)	(83)	(84)	(85)	(86)	(87)	(88)	(89)	(90)	(91)	(92)	(93)	(94)	(95)	(96)	(97)	(98)	(99)	(100)	(101)	(102)	(103)	(104)	(105)	(106)	(107)	(108)	(109)	(110)	(111)	(112)	(113)	(114)	(115)	(116)	(117)	(118)	(119)	(120)	(121)	(122)	(123)	(124)	(125)	(126)	(127)	(128)	(129)	(130)	(131)	(132)	(133)	(134)	(135)	(136)	(137)	(138)	(139)	(140)	(141)	(142)	(143)	(144)	(145)	(146)	(147)	(148)	(149)	(150)	(151)	(152)	(153)	(154)	(155)	(156)	(157)	(158)	(159)	(160)	(161)	(162)	(163)	(164)	(165)	(166)	(167)	(168)	(169)	(170)	(171)	(172)	(173)	(174)	(175)	(176)	(177)	(178)	(179)	(180)	(181)	(182)	(183)	(184)	(185)	(186)	(187)	(188)	(189)	(190)	(191)	(192)	(193)	(194)	(195)	(196)	(197)	(198)	(199)	(200)	(201)	(202)	(203)	(204)	(205)	(206)	(207)	(208)	(209)	(210)	(211)	(212)	(213)	(214)	(215)	(216)	(217)	(218)	(219)	(220)	(221)	(222)	(223)	(224)	(225)	(226)	(227)	(228)	(229)	(230)	(231)	(232)	(233)	(234)	(235)	(236)	(237)	(238)	(239)	(240)	(241)	(242)	(243)	(244)	(245)	(246)	(247)	(248)	(249)	(250)	(251)	(252)	(253)	(254)	(255)	(256)	(257)	(258)	(259)	(260)	(261)	(262)	(263)	(264)	(265)	(266)	(267)	(268)	(269)	(270)	(271)	(272)	(273)	(274)	(275)	(276)	(277)	(278)	(279)	(280)	(281)	(282)	(283)	(284)	(285)	(286)	(287)	(288)	(289)	(290)	(291)	(292)	(293)	(294)	(295)	(296)	(297)	(298)	(299)	(300)	(301)	(302)	(303)	(304)	(305)	(306)	(307)	(308)	(309)	(310)	(311)	(312)	(313)	(314)	(315)	(316)	(317)	(318)	(319)	(320)	(321)	(322)	(323)	(324)	(325)	(326)	(327)	(328)	(329)	(330)	(331)	(332)	(333)	(334)	(335)	(336)	(337)	(338)	(339)	(340)	(341)	(342)	(343)	(344)	(345)	(346)	(347)	(348)	(349)	(350)	(351)	(352)	(353)	(354)	(355)	(356)	(357)	(358)	(359)	(360)	(361)	(362)	(363)	(364)	(365)	(366)	(367)	(368)	(369)	(370)	(371)	(372)	(373)	(374)	(375)	(376)	(377)	(378)	(379)	(380)	(381)	(382)	(383)	(384)	(385)	(386)	(387)	(388)	(389)	(390)	(391)	(392)	(393)	(394)	(395)	(396)	(397)	(398)	(399)	(400)	(401)	(402)	(403)	(404)	(405)	(406)	(407)	(408)	(409)	(410)	(411)	(412)	(413)	(414)	(415)	(416)	(417)	(418)	(419)	(420)	(421)	(422)	(423)	(424)	(425)	(426)	(427)	(428)	(429)	(430)	(431)	(432)	(433)	(434)	(435)	(436)	(437)	(438)	(439)	(440)	(441)	(442)	(443)	(444)	(445)	(446)	(447)	(448)	(449)	(450)	(451)	(452)	(453)	(454)	(455)	(456)	(457)	(458)	(459)	(460)	(461)	(462)	(463)	(464)	(465)	(466)	(467)	(468)	(469)	(470)	(471)	(472)	(473)	(474)	(475)	(476)	(477)	(478)	(479)	(480)	(481)	(482)	(483)	(484)	(485)	(486)	(487)	(488)	(489)	(490)	(491)	(492)	(493)	(494)	(495)	(496)	(497)	(498)	(499)	(500)	(501)	(502)	(503)	(504)	(505)	(506)	(507)	(508)	(509)	(510)	(511)	(512)	(513)	(514)	(515)	(516)	(517)	(518)	(519)	(520)	(521)	(522)	(523)	(52
--	-----	-----	-----	-----	-----	-----	-----	-----	-----	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-------	-----

[illegible][illegible][illegible][illegible][illegible]

	1970	1980	1990	2000	2006
Population (millions)	1.1	1.2	1.3	1.4	1.5
GDP per capita (\$1000)	1.5	2.5	3.5	4.5	5.5
Life expectancy at birth (years)	55	65	75	80	82
Urban population (%)	20	30	40	50	55
Employment in agriculture (%)	60	50	40	30	25
Government expenditure on health (% GDP)	1.0	1.5	2.0	2.5	3.0
Healthcare workers per 1000 people	0.5	0.8	1.2	1.5	1.8
Infant mortality rate (per 1000 live births)	100	80	60	40	35
Mortality rate from HIV/AIDS (per 100,000 people)	0	0	0	0	0.5

[illegible][illegible][illegible][illegible]

18. A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

5

19. A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

20. A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

21. A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.


22. A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

23. A vaccination method comprising the steps of:
a). removing cancer cells sensitive to the compounds below from a patient;
b). treating the cancer cells *in vitro* with an effective amount of a composition comprising the compound of Claim 12 and pharmaceutically acceptable salts thereof.

30

10044869-01-002

24. A compound selected from the group consisting of the formulas:



where R_2 is an aliphatic chain having 10 to 18 carbons; and

R_3 is a tertiary amine.

5

25. The compound of Claim 24 wherein R_3 is pyrrolidino.

26. A method for inhibiting the growth of cancer cells in a mammal comprising the step of administering to the mammal a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

27. A method for treating a patient having sphingolipidosis by reducing glycosphingolipid synthesis comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

28. A method for treating a patient having a microbial or viral infection comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

29. A method for treating a patient having a drug resistant tumor, comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

30. A method for reducing tumor angiogenesis in a patient comprising the step of administering to the patient a therapeutically effective amount of a composition comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

31. A vaccination method comprising the steps of:

- a). removing cancer cells sensitive to the compounds below from a patient;
- b). treating the cancer cells *in vitro* with an effective amount of a composition

5 comprising the compound of Claim 24 and pharmaceutically acceptable salts thereof.

2007-06-28 10:00